BRPI0922152A2 - Compostos - Google Patents

Compostos

Info

Publication number
BRPI0922152A2
BRPI0922152A2 BRPI0922152-2A BRPI0922152A BRPI0922152A2 BR PI0922152 A2 BRPI0922152 A2 BR PI0922152A2 BR PI0922152 A BRPI0922152 A BR PI0922152A BR PI0922152 A2 BRPI0922152 A2 BR PI0922152A2
Authority
BR
Brazil
Prior art keywords
compounds
Prior art date
Application number
BRPI0922152-2A
Other languages
English (en)
Inventor
Srinivisa Rao Akireddy
Balwinder Singh Bhatti
Timothy J Cuthbertson
Craig Harrison Miller
Joseph Pike Mitchener Jr
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of BRPI0922152A2 publication Critical patent/BRPI0922152A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
BRPI0922152-2A 2008-12-01 2009-11-30 Compostos BRPI0922152A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11888508P 2008-12-01 2008-12-01
PCT/US2009/066083 WO2010065447A2 (en) 2008-12-01 2009-11-30 Novel compounds

Publications (1)

Publication Number Publication Date
BRPI0922152A2 true BRPI0922152A2 (pt) 2015-08-18

Family

ID=41549744

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0922630A BRPI0922630A2 (pt) 2008-12-01 2009-11-30 "(r)-3-(e)-2-(pirrolidin-33-il)vinil)-5-(tetra-hidropiran-4-ilóxi)piridina, seus sais, suas sínteses e seus usos como ligantes para receptores acetilcolinérgico nicotínicos"
BRPI0922152-2A BRPI0922152A2 (pt) 2008-12-01 2009-11-30 Compostos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0922630A BRPI0922630A2 (pt) 2008-12-01 2009-11-30 "(r)-3-(e)-2-(pirrolidin-33-il)vinil)-5-(tetra-hidropiran-4-ilóxi)piridina, seus sais, suas sínteses e seus usos como ligantes para receptores acetilcolinérgico nicotínicos"

Country Status (27)

Country Link
US (3) US8633227B2 (pt)
EP (3) EP2896619A1 (pt)
JP (2) JP5615836B2 (pt)
KR (2) KR20110094318A (pt)
CN (2) CN102227406B (pt)
AR (1) AR074239A1 (pt)
AU (2) AU2009322628A1 (pt)
BR (2) BRPI0922630A2 (pt)
CA (2) CA2744197A1 (pt)
CL (2) CL2009002146A1 (pt)
CO (1) CO6382158A2 (pt)
EA (1) EA021054B1 (pt)
EC (1) ECSP11011135A (pt)
ES (1) ES2403022T3 (pt)
IL (2) IL212799A (pt)
MX (2) MX2011005712A (pt)
MY (1) MY159040A (pt)
NZ (1) NZ593058A (pt)
PE (1) PE20100467A1 (pt)
RU (1) RU2507197C2 (pt)
SA (1) SA109300715B1 (pt)
SG (2) SG171876A1 (pt)
TW (1) TW201024283A (pt)
UA (1) UA106217C2 (pt)
UY (1) UY32278A (pt)
WO (2) WO2010065449A1 (pt)
ZA (1) ZA201103497B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266097B (en) * 2008-12-01 2022-07-01 Oyster Point Pharma Inc Mono-orotate acid addition salt of r(–5–)–e(–2–)pyrrolidine––3ylvinyl)pyrimidine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
US20130196340A1 (en) * 2012-01-30 2013-08-01 Roar Holding Llc Ex vivo plasma enzyme activity assay using inhibitors as a negative control
PE20151301A1 (es) 2013-02-05 2015-09-16 Purdue Pharma Lp Formulaciones farmaceuticas resistentes a la manipulacion indebida
US20160262372A1 (en) * 2015-03-13 2016-09-15 Cornell Kunz Extermination Treatment Appliance And Method
NZ746468A (en) 2016-04-07 2023-06-30 Oyster Point Pharma Inc Methods of treating ocular conditions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
JP3745433B2 (ja) * 1995-02-02 2006-02-15 第一製薬株式会社 複素環式化合物
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
CA2264569C (en) * 1996-09-13 2003-11-11 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
JPH1171345A (ja) * 1997-08-30 1999-03-16 Nippon Nohyaku Co Ltd 光学活性なピロリジン誘導体及びその中間体並びにそれらの製造法
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
EP1302458A4 (en) * 2000-07-11 2005-10-19 Banyu Pharma Co Ltd ESTERDERIVATE
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
WO2007054777A1 (en) * 2005-11-09 2007-05-18 Orchid Chemicals & Pharmaceuticals Limited Depletion of isomer in cephalosporin antibiotic
AU2007249194B2 (en) * 2006-05-12 2012-11-22 Myrexis, Inc. Therapeutic compounds and their use in cancer

Also Published As

Publication number Publication date
ES2403022T3 (es) 2013-05-13
KR20110094100A (ko) 2011-08-19
JP5615836B2 (ja) 2014-10-29
UA106217C2 (en) 2014-08-11
EP2358705A1 (en) 2011-08-24
HK1157778A1 (en) 2012-07-06
MX2011005713A (es) 2011-06-17
MY159040A (en) 2016-12-15
CA2744197A1 (en) 2010-06-10
EP2358670A2 (en) 2011-08-24
US20120015983A1 (en) 2012-01-19
UY32278A (es) 2011-06-30
ZA201103497B (en) 2012-01-25
AU2009322630A1 (en) 2010-06-10
SA109300715B1 (ar) 2014-06-25
CN102232072B (zh) 2014-09-24
CL2009002146A1 (es) 2010-04-30
EP2358670B1 (en) 2012-10-24
IL212799A (en) 2013-12-31
JP5698673B2 (ja) 2015-04-08
WO2010065447A3 (en) 2010-07-22
JP2012510472A (ja) 2012-05-10
EA021054B1 (ru) 2015-03-31
SG171432A1 (en) 2011-07-28
RU2507197C2 (ru) 2014-02-20
CL2009002145A1 (es) 2010-04-30
JP2012510473A (ja) 2012-05-10
CN102232072A (zh) 2011-11-02
CA2744191A1 (en) 2010-06-10
CO6382158A2 (es) 2012-02-15
BRPI0922630A2 (pt) 2016-01-05
SG171876A1 (en) 2011-07-28
RU2011127004A (ru) 2013-01-10
AR074239A1 (es) 2010-12-29
WO2010065449A1 (en) 2010-06-10
WO2010065447A2 (en) 2010-06-10
TW201024283A (en) 2010-07-01
NZ593058A (en) 2013-06-28
US20140107163A1 (en) 2014-04-17
KR20110094318A (ko) 2011-08-23
EA201170736A1 (ru) 2011-12-30
US20110269975A1 (en) 2011-11-03
US8153821B2 (en) 2012-04-10
CN102227406B (zh) 2013-07-31
MX2011005712A (es) 2011-06-17
IL212799A0 (en) 2011-07-31
CN102227406A (zh) 2011-10-26
PE20100467A1 (es) 2010-08-03
ECSP11011135A (es) 2011-07-29
IL212796A0 (en) 2011-07-31
AU2009322628A1 (en) 2010-06-10
EP2896619A1 (en) 2015-07-22
US8633227B2 (en) 2014-01-21

Similar Documents

Publication Publication Date Title
NO2025030I1 (no) Atezolizumab - forlenget
FIC20250007I1 (fi) Fidanakogeenielaparvoveekki
NO2021048I1 (no) satralizumab
NO2017048I1 (no) lotilaner
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
DK2242759T3 (da) Forbindelser
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
BRPI0907376A2 (pt) Fotobiorretador
BRPI0914649A2 (pt) Piprazolo-quinazolinas
SMT201600045B (it) Composti tetraciclinici c7-fluoro sostituiti
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2297162T3 (da) Forbindelser
EP2308156A4 (en) STEP ACTUATOR
DE602008003970D1 (de) Strahlstromkalibriersystem
BRPI0907522A2 (pt) biarlamidas
BRPI0916432A2 (pt) compostos
DE112009000183A5 (de) Sicherheitsvorreiber
BRPI0923592A2 (pt) composto
BRPI0909634A2 (pt) 2-aminoquinolinas
DE112009001946A5 (de) Mobelauszugsführung
BRPI0911393A2 (pt) composto de 5-hidroxipirimidina-4-carboxamida
BRPI0909637A2 (pt) 2-aminoquinolinas
DK2206698T3 (da) Ethynylindolforbindelser

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]